Intestinal Research

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial

Tadakazu Hisamatsu, Reiko Kunisaki, Shiro Nakamura, Tomoyuki Tsujikawa, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Kaoru Yokoyama, Masakazu Nagahori, Takanori Kanai, Makoto Naganuma, Hirofumi Michimae, Akira Andoh, Akihiro Yamada, Tadashi Yokoyama, Noriko Kamata, Shinji Tanaka, Yasuo Suzuki, Toshifumi Hibi, Mamoru Watanabe,

Intest Res. 2018;16(3):494-498. Published online July 27, 2018
DOI: https://doi.org/10.5217/ir.2018.16.3.494

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial

Intestinal Research. 2018;16(3):494

Link1 Link2 Link3

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis

G. G. KAPLAN, C. HUR, J. KORZENIK, B. E. SANDS

Alimentary Pharmacology & Therapeutics. 2007;26(11-12):1509-1520

Link1

Mo1689 SIBDQ Score Does Not Predict the Need for Dose Escalation of Infliximab in Inflammatory Bowel Disease Patients

Alyssa M. Parian, Bonny Thul, Sharon Dudley-Brown, Mark Lazarev

Gastroenterology. 2012;142(5):S-660

Link1 Link2

P054 WEEK 10 INFLIXIMAB CONCENTRATION IDENTIFIES PATIENTS THAT REQUIRE EARLY DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE

Mark Salem, Christina Ha, Gaurav Syal

Gastroenterology. 2019;156(3):S38

Link1 Link2

P054 WEEK 10 INFLIXIMAB CONCENTRATION IDENTIFIES PATIENTS THAT REQUIRE EARLY DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE

Mark Salem, Christina Ha, Gaurav Syal

Inflammatory Bowel Diseases. 2019;25(Supplement_1):S27-S27

Link1

Su1225 Concomitant Elemental Diet Therapy Is Effective in Sustaining Infliximab Scheduled Maintenance Therapy in Patients With Crohn's Disease to Prevent Loss of Response

Noriko Kamata, Kenji Watanabe, Takuya Tsukahara, Yoshie Hagihara, Kenichi Morimoto, Atsushi Noguchi, Takako Miyazaki, Mitsue Sogawa, Hirokazu Yamagami, Tetsuya Tanigawa, Masatsugu Shiba, Toshio Watanabe, Kazunari Tominaga, Yasuhiro Fujiwara, Tetsuo Arakawa

Gastroenterology. 2013;144(5):S-433

Link1 Link2

94 Treatment of Secondary Infliximab Failure in Crohn's Disease Based on Serum Levels of Infliximab and Antibodies Against Infliximab: The Danish Study of Optimizing Infliximab Therapy in Crohn's Disease (Do It Crohn) Randomized Clinical Trial

Casper Steenholdt, Jorn Brynskov, Ole. Thomsen, Lars K. Munck, Jan Fallingborg, Lisbet A. Christensen, Gitte Pedersen, Jens Kjeldsen, Bent A. Jacobsen, Anne Sophie Oxholm, Jakob Kjellberg, Klaus Bendtzen, Mark A. Ainsworth

Gastroenterology. 2013;144(5):S-22

Link1 Link2

Safety and effectiveness of endoscopic pneumatic dilatation+infliximab combined therapy in stenosing Crohn disease

F. Barberani, S. Boschetto, A. Gigliozzi, M. Giovannone, M. Tosoni

Digestive and Liver Disease. 2006;38:S15

Link1 Link2

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

Javier P Gisbert, Julián Panés

The American Journal of Gastroenterology. 2009;104(3):760-767

Link1

Link2 Link3

Infliximab dose escalation not uncommon during first year in RA

PharmacoEconomics & Outcomes News. 2006;494(1):4-4

Link1

Link2 Link3